ATR Inhibitor ATRN-119 clinical trials
Also written ATRN-119.
How each study uses ATR Inhibitor ATRN-119 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the ATR Inhibitor ATRN-119 studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ATRN-119
- 3
Studies by the year they started
2 studies that test it; most in 2023 (1); 1 more planned to start later
| Year | Studies |
|---|---|
| 2023 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 1 · Other 2
Aprea Therapeutics (1) · Abramson Cancer Center at Penn Medicine (1) · Washington University School of Medicine (1)
Related medicines
As reviewed, each with the page that says it.
- One of Protein Kinase Inhibitors source
Studies
Open first, then newest update. How each study uses ATR Inhibitor ATRN-119 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSRecruitingPhase 1Washington University School of MedicineNCT07617363Written as ATRN-119How we know
- Combining Neo-adjuvant ATR-inhibition With Nodal SBRT for Early-stage Resectable HPV+ OPSCCsNot yet recruitingPhase 1/2Abramson Cancer Center at Penn MedicineNCT07578467Written as ATRN-119How we know
- Study Of ATRN-119 In Patients With Advanced Solid TumorsCompletedPhase 1/2Aprea TherapeuticsNCT04905914Written as ATRN-119How we know
What changed recently
From the registry's own updates since Oct 23, 2026.
Started recruiting1
- ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDSNov 12, 2026NCT07617363